Merger Opportunity Vapotherm recently closed a merger with an affiliate of Perceptive Advisors, signaling potential for accelerated growth, expanded capital, and new strategic partnerships that can open cross-sell opportunities to their enhanced customer base and distribution channels.

Growth Revenue With reported Q2 2024 financial results and a revenue base in the mid double-digit millions, there is momentum to position high velocity therapy as a cost-effective, high-value solution for hospitals' ED and ICU respiratory care, plus potential upsell to additional patient populations.

Clinical Differentiator Vapotherm’s Precision Flow high velocity therapy offers mask-free, heated humidified high-flow support for multiple populations, which can be pitched to hospitals seeking less invasive, more comfortable respiratory support solutions and potential integration with existing oxygenation workflows.

Technology Enablement Utilize Vapotherm’s tech stack familiarity (MATLAB, SOLIDWORKS, Terraform, Docker, enterprise collaboration tools) to target mid-market hospitals and clinical engineering teams with compelling, model-based ROI analyses and seamless integration narratives into hospital IT and device management ecosystems.

Expansion Targets Given the company’s size and the competitive landscape, focus on hospitals and health systems undergoing modernization in respiratory care, leveraging Merger-backed growth to access larger procurement programs, channel partners, and potential international expansion opportunities.